EVOLUS, INC. Restructuring and Related Cost, Number of Positions Eliminated
EVOLUS, INC. (EOLS) reported Restructuring and Related Cost, Number of Positions Eliminated of 100 position for the 1-month period ending 2020-04-30, per its 10-K filed 2021-03-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated · last filed 2021-03-25
- 2020-04-30: Restructuring and Related Cost, Number of Positions Eliminated 1 month 100.00 position.
| Period end | Restructuring and Related Cost, Number of Positions Eliminated 1 month |
|---|---|
| 2020-04-30 | 100.00 position 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |